Abstract: Fluoride varnish compositions for temporary application and adhesion to a person's teeth include a carrier that remains stable and translucent during storage. The compositions include a carrier comprising a stable and translucent resin and a fluoride ion source (e.g., a fluoride salt such as sodium fluoride) dispersed within the carrier so as to provide biologically available fluoride ions to teeth being treated. The carrier resists formation of solids that can plug a 25 gauge or smaller syringe brush applicator tip. The compositions may also include an adhesion promoting agent comprising an alkyl phosphoric acid. The composition adheres only temporarily to tooth tissue (e.g., for a period of at least about 4 minutes, but not more than about 1 year), after which the composition spontaneously wears away as a natural result of the action of the tongue, saliva and/or other factors.

Abstract: The present invention generally relates to a wet wipe or sheet that is suitable for contacting the skin and removing mucus from the skin. More specifically, the present invention relates to a wet wipe having an aqueous saline component suitable for dissolving and removing mucus in combination with the fabric matrix of the wet wipe. Typically, the fabric matrix of the wet wipe has a capacity of about 125 grams of solution per square meter, and it is impregnated with the aqueous saline solution to a level at or below approximately 80% of the absorbent capacity of the matrix.

Abstract: The invention relates to mixtures of alkyl sulfosuccinate monoesters of general formulas (I) and/or (II), in which R represents a linear or branched, saturated or unsaturated alkyl group having 6 to 22 C atoms, and X and Y independently represent a hydrogen atom or a cation that can form a water-soluble salt and is selected from among the group composed of alkali metal, alkaline earth metal, ammonia, and organic ammonia. The invention is characterized in that the mixture contains 30 to 70 percent by weight of C16 alkyl sulfosuccinate monoester and 30 to 70 percent by weight of C18 alkyl sulfosuccinate monoester, the percentages by weight being in relation to the total amount of alkyl sulfosuccinate monoesters of formulas (I) and (II). The invention also relates to the use of said mixtures in cosmetic and/or pharmaceutical preparations.

Abstract: A water-based composition containing oil soluble components may include an anhydrous concentrate including hydroxypropylcocoate PEG-8 dimethicone and a hydration component, which may be stored in separate vessels prior to mixing. The anhydrous concentrate may be combined with the hydration component to create a consumer product such as a topical cream. The anhydrous concentrate may include a preparation that includes a liquid dispersion polymer, an inverting surfactant and a binding agent, and also may include lipid-soluble vitamins, antioxidants and the like. The hydration component may include water and a preservative system, and also may include water-soluble vitamins, antioxidants and the like. Two forms (i.e. lipid-soluble and water-soluble) of a given ingredient (such as vitamin C) may be provided in the concentrate and the hydration component, respectively.

Abstract: Notch filter coatings for use in sunscreen applications are provided herein. An exemplary composition includes multiple zinc oxide particles suspended within a medium forming sunscreen composition; and a combination of multiple notch filter coating materials individually applied as a distinct layer to each of the multiple zinc oxide particles to create a multi-layered structure surrounding each of the multiple zinc oxide particles within the sunscreen composition, wherein the multi-layered structure: reflects light at a user-determined wavelength range based on the wavelength range at which each of the multiple notch filter coating materials reflects light; and allows wavelengths of light (i) within at least a portion of the ultraviolet spectrum and (ii) outside of the user-determined wavelength range to be absorbed by the multiple zinc oxide particles.

Abstract: Techniques for implementing organic materials in sunscreen applications are provided herein. A method includes selecting a combination of multiple organic materials to incorporate into a sunscreen composition, wherein said selecting is based on (i) a desired absorption spectrum of the sunscreen composition, (ii) the absorption spectrum of each of the multiple organic materials, and (iii) a particle size limitation for each of the multiple organic materials, and incorporating the selected combination of organic materials into the sunscreen composition to generate the desired absorption spectrum. A composition includes a combination of multiple organic materials incorporated into a sunscreen composition, wherein the combination of organic materials is selected based on (i) a desired absorption spectrum of the sunscreen composition, (ii) the absorption spectrum of each of the multiple organic materials, and (iii) a particle size limitation for each of the multiple organic materials.

Abstract: Disclosed are oral care compositions, for example dentifrice compositions, comprising an oral care composition comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and at least one amino acid capable of chelating the metal oxide. The composition may comprise a polymeric adherent material for adhering the metal oxide particles in the dentin tubule. The metal oxide particles have a median particle size of 5 microns or less, and may comprise zinc oxide.

Abstract: Described herein are methods and compositions useful for enhancing pigmentation, such as skin, eye and/or hair pigmentation comprising administering e.g., an NNT inhibitor or an agent that modifies redox status in a melanocyte.

Abstract: The invention is directed to a cosmetic composition and the precursor thereof. The composition has solid agent and liquid agent, both of which are cosmetic benefit ingredients. The solubility of solid agents in liquid agents in the inventive compositions is enhanced in the presence of a tricyclodecane amide.

Abstract: Arbutin-containing compositions are useful for topical application to provide enhanced luminosity, brightening or lightening to the skin of a user and are at least 85% as efficacious (with regard to skin lightening, when used alone or in a system as measured by Chromameter® b* parameter values) as substantially corresponding compositions containing hydroquinone in an mount from about the same molar amount to about 1.5 times the molar amount of arbutin.

Abstract: The present invention generally relates to oral care compositions which enhance the solubility of rutin comprising rutin and at least one polyhydroxyalkyl alcohol. The present invention also relates to methods for use and manufacturing said oral care compositions.

Abstract: Described herein are tooth whitening strips comprising an hydratable adhesive film having a granular bleaching ingredient attached thereto, wherein upon hydration, the granular bleaching ingredient releases hydrogen peroxide which is used by an enzyme catalyst having perhydrolytic activity to enzymatically produce an effective amount of peracid bleaching agent from an acyl donor substrate. Methods of making and use the tooth whitening strips are also provided.

Abstract: The present invention provides a composition for facial contouring, comprising a mixture of botulinum toxin and air, and a method of facial contouring using the same. When the mixture of botulinum toxin and air is injected into an SMAS layer, the mixture strengthens the SMAS layer and draws back the galea aponeurotica to effectively lift up the face or change the facial contour, thus effectively enhancing the effect of facial contouring.

Abstract: Disclosed are hair styling compositions comprising at least two latex acrylate polymers, wherein at least one latex acrylate polymer is a film-forming polymer. Methods of styling the hair are also disclosed.

Abstract: Disclosed are hair styling compositions comprising at least two latex acrylate polymers, wherein at least one latex acrylate polymer is a film-forming polymer, and at least one component chosen from thickening agents. Methods of styling the hair are also disclosed.

Abstract: Disclosed are hair styling compositions comprising at least two latex polymers, wherein at least one latex polymer is a film-forming polymer. The composition is capable of forming a film having certain properties on a substrate. Methods of styling the hair are also disclosed.

Abstract: A solid cosmetic composition includes a vegetable butter. The solid composition has dispersed therein gas bubbles, and the gas bubbles form at least 20% of the volume of the solid cosmetic composition.

Abstract: A cosmetic composition comprises a coffee cherry preparation, and most preferably an extract from a sub-ripe quick-dried coffee cherry. Particularly contemplated cosmetic compositions are formulated as a shampoo, lotion, cream, balm, or ointment, and will have at least one of an antioxidant effect, an anti-inflammatory effect, a UV-protective effect, an antimutagenic effect, a chemoprotective effect, a scar reducing effect, a skin-lightening effect, a moisturizing effect, a wrinkle reduction effect, and an antibacterial effect.

Abstract: A solid cosmetic composition includes (i) sugar; (ii) a vegetable fiber, a fruit fiber or mixture thereof; and (iii) a soap. The solid cosmetic composition is prepared by dehydrating a liquid composition including (i) sugar in an amount of 33.75 to 47 wt. %; (ii) a vegetable fiber, a fruit fiber or mixture thereof, in an amount of 3.75 to 4.75 wt. %; (iii) a soap in an amount of 20 to 75 wt. %; and (iv) water in an amount of 11 to 15 wt. %. The amounts are based on the total combined amount of the sugar, the fiber, the soap and the water.

Abstract: Provided are dental cleaning compositions, methods of using and methods of using such compositions which minimize gum damage in the oral cavity. In one form, the dental cleaning composition includes a substantially stoichiometric ratio of one or more oxidizing agents to one or more reducing agents in one or more one or more orally acceptable carriers; where the substantially stoichiometric ratio of one or more oxidizing agents to one or more reducing agents is sufficient to neutralize the oxidizing agent in a subject oral cavity; and where the one or more oxidizing agents and one or more reducing agents are either co-dispensed or sequentially dispensed in the subject oral cavity.

Abstract: Provided is a moisturizing, anti-wrinkle, and anti-allergic traditional Chinese medicine composition and a preparation method thereof. The traditional Chinese medicine composition has an aqueous extract of Dendrobium nobile, Viola tricolor, Ophiopogon japonicus, Tremella fuciformis, and an oat material as active ingredient. The oat material is oat grains, oat flour, or oat bran. In the composition, the Dendrobium nobile, Viola tricolor, Ophiopogon japonicus, Tremella fuciformis and oat material have a weight ratio of 5-15:2-10:2-10:1-5:1-5, and preferably 12:6:3:2:2. The Dendrobium nobile, Viola tricolor, Ophiopogon japonicus, oat material, and Tremella fuciformis are combined and extracted for external use, with which moisturizing and also delaying skin aging, anti-allergic and anti-chapping efficacies are achieved by means of water retention, maintenance of normal physiological functions of aquaporins, and others.

Abstract: In various implementations, a dental hygiene system may include a dental powder. The dental powder may include one or more compounds comprising calcium and/or magnesium. The dental powder may include one or more probiotics, in some implementations. The dental hygiene system (e.g., dental powder) may include bismuth subsalicylate. The dental hygiene system may include an applicator and the dental powder may be applied to the applicator. A user may use the dental hygiene system to improve a user's dental hygiene.

Abstract: In one aspect, an ingestible, electrical device, comprises a substrate comprising a reservoir that is configured to hold one or more substances; a first film covering the reservoir, wherein the first film is at least partially metallic; a charge storage system connected to the first film, the charge storage system configured to deliver a transient electrochemical potential to the first film; wherein the first film is configured to prevent exposure of the substance to an aqueous environment in an organism, while the charge storage system delivers the transient electrochemical potential to the first film; and wherein the first film is configured for dissolution to expose the one or more substances to the aqueous environment in the organism, after the charge storage system stops delivering the transient electrochemical potential to the first film.

Abstract: A method for promoting muscle or tendon regeneration, and/or arteriogenesis in a subject includes administering to the subject a pharmaceutical composition that contains a synthetic peptide, which has an amino acid sequence that has 20-39 amino acid residues and has at least 20 consecutive residues that has at least 90% amino acid sequence identity to residues 11-30 of SEQ ID NO: 1. The synthetic peptide may have the amino acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 8, or SEQ ID NO: 9.

Abstract: The present invention provides methods of delivering a composition comprising nanoparticles that comprise a macrolide and an albumin by directly injecting the nanoparticle composition into the blood vessel wall or the tissue surrounding the blood vessel wall. The methods can be used for inhibiting negative remodeling or vascular fibrosis in the blood vessel and are useful for treating various diseases.

Abstract: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short Tmax). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.

Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.

Abstract: The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, nm) of 100-500 nm, where the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc.

Abstract: The present invention teaches a foamable pharmaceutical and cosmetic compositions comprising an aprotic polar solvent; foam compositions and uses thereof.

Abstract: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m2/g to about 2.8 m2/g (e.g., from about 0.1 m2/g to about 1.3 m2/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided.

Abstract: The present invention provides methods of lyophilizing a pharmaceutical substance involving a primary drying step executed at a product temperature at or above the collapse temperature. The invention also provides pharmaceutical substances lyophilized at or above the collapse temperature.

Abstract: Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis.

Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.

Abstract: A once daily controlled release pharmaceutical compositions comprising tapentadol, wherein preferably the mean Tmax of tapentadol is reached after 10 hours of administration of the composition. The composition comprises tapentadol, such that it maintains serum concentration of tapentadol of at least about 20 ng/ml for at least about 17 hours after oral administration of the composition. According to one embodiment the controlled release pharmaceutical composition comprises tapentadol, which is gastroretentive.

Abstract: The present invention relates to generation of cell lines expressing recombinant proteins for use in naked and encapsulated cell biodelivery of secreted therapeutic molecules. In one embodiment the cell line is human. In another aspect of the invention the transposon system is used for generating a cell line for secretion of a biologically active polypeptide.

Abstract: The present invention proposes a design to incorporate drug(s) in the hard capsule shells (body and cap) composition. Drug(s) in the cap and body of the capsule shell may be the same or may be different. Other drug(s) in the form of granules, beads etc. can be filled into the capsules as a core material. The drug(s) in the capsule core material may be the same as in the shell-composition or may be different. Thus, the same capsule may contain different drug(s) as the core material and in the shell. The key advantages of incorporation of drug in the capsule shell compositions are to minimize drug-drug interaction and to obtain a desired rate of release of the drug(s), mainly for potent ones. The concept can be applied to the hard gelatin, and hard non-gelatin capsules.

Abstract: The present invention refers to new microspheres including pancreatic enzymes, pharmaceutical compositions containing them, and a process to obtain them. The process here described doesn't involve the use of solvents and proves to be remarkably shorter and efficient than the producing methods of the prior arts. The microspheres obtained, including one or more pancreatic enzymes, one or more hydrophilic low-melting polymers and eventual excipients, have an high enzymatic activity, bio-availability and stability.

Abstract: Nanoparticulate compositions are disclosed. The nanoparticulate compositions typically include at least one, preferably two or more, active agent(s), one of which is an immunomodulatory compound, loaded into, attached to the surface of and/or enclosed within a delivery vehicle. The delivery vehicles can be nanolipogels including a polymeric core and a lipid shell or a biodegradable polymeric nanoparticle such as a PLGA nanoparticle. Typically, at least one of the active agents is an immunomodulator that increases an immune stimulatory response or decreases an immune suppressive response. In some embodiments, the particle includes both an immunomodulator that increases an immune stimulatory response and an immunomodulator that decreases an immune suppressive response. The particles can be decorated with a targeting moiety that improves delivery to a target cell. Methods of using the compositions to enhance an immune response and treat diseases such as cancer are also disclosed.

Abstract: A system for manufacturing an artificial construct suitable for transplantation into a biological organism that includes a two or three three-dimensional preform that is based on the actual two or three-dimensional structure of a native mammalian tissue; and an electrospinning apparatus, wherein the electrospinning apparatus is operative to deposit at least one layer of polymer fibers on the preform to form a polymer scaffold, and wherein the orientation of the fibers in the scaffold relative to one another is substantially parallel.

Abstract: Apparatus and methods for treatment of an internal cavity are provided. The internal cavity is coated with a treatment solution. The treatment solution can include a solidifiable matrix with or without a drug or combination of drugs incorporated therein, or a drug solution without a solidifiable matrix. The treatment solution is coated onto at least a portion of the internal cavity, and acts as a slow-release drug delivery system.

Abstract: A oral pharmaceutical composition for controlled release of an opioid from a pharmaceutical composition is described that comprises (i) an erodible matrix composition comprising a mixture of (a) a polymer or a mixture of polymers (b) an opioid, and optionally, (c) one or more pharmaceutically acceptable excipients; and (ii) a single, substantially insoluble in and impermeable coating having two openings exposing at least one surface of the matrix, and comprising one or more polymers. The composition exhibits controlled release of the opioid by erosion of the matrix and exhibits a zero order release profile wherein about 75% w/w of the opioid is released from the composition within 4-10 hours when tested in a dissolution test as described herein.

Abstract: The present invention relates to a backing for a water-based patch consisting of the following constituents, wherein the backing is excellent in pasty preparation retention and moisture retention, improves the persistence of drug efficacy by inhibiting the sublimation of the drug, gives neither restrained feeling nor rough feeling due to a thin thickness and an excellent elasticity, controls the moisture permeability, gives almost no sticky feeling and thereby gives an excellent feeling in application. A patch backing for a water-based pasty preparation consisting of a laminate, wherein the laminate consists of three layers, a film layer having through-holes is laminated between a nonwoven fabric layer A and a nonwoven fabric layer B, said film layer consists of a resin containing an olefin elastomer, the through-hole area per a hole is 0.02-0.18 mm2, and the opening ratio of the through-hole is 1-10%.

Abstract: The present invention provides methods of ameliorating or reducing the extent of cardiac arrhythmia disorders, by administering an inhibitor of histone deacetylase enzyme (HDAC).

Abstract: The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.

Abstract: A nutritional composition is used to reconstitute an optimal healthy microbiota ecosystem in humans or animals. In particular, an ingestible carrier contains specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. In another aspect, specific amino acids are used to reconstitute an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people.

Abstract: The present invention relates to methods of preventing a psychotic disorder in a subject in need of intervention including administering to the subject a composition including EPA (eicosapentanoic acid) and DHA (docosahexaenoic acid). Methods of treating pre-psychotic symptoms in a subject, including administering to the subject a composition including EPA and DHA are also included.

Abstract: Methods and compositions for hydrating cats. Cats fed diets containing certain amounts and ratios of arachidonic acid and eicosapentaenoic acid will be sufficiently hydrated and at reduced risk for development of urinary stones, feline idiopathic cystitis, or FLUTD.

Abstract: The present invention provides uses of chlorogenic acid in the preparation of medicaments for treatment of psoriasis. Chlorogenic acid, a small molecular compound, is a biological response modifier focusing on the overall regulation, and has a good effect on rebuilding the homeostasis of immune function. Harmful action of chlorogenic acid on liver and kidney is not found, and it can be long-term used, without toxic and side effects on body. Chlorogenic acid is safe and effective, with low recurrence rate, and it can improve life quality of patients. It has an obvious effect on psoriasis, especially on psoriasisvulgaris and psoriasis pustulosa, thus for treatment of psoriasis, chlorogenic acid has a wide application prospects.

Abstract: The present invention relates to a pharmaceutical composition containing 8 compounds: trilinolein, 1-olein-2,3-dilinolein, 1-palmitin-2,3-dilinolein, 1,3-diolein-2-linolein, 1-palmitin-2-linolein-3-olein, 1,3-dipalmitin-2-linolein, triolein and 1-palmitin-2,3-diolein. The invention also relates to pharmaceutical preparations of this composition and the use thereof in the treatment of tumors and in the immuno-enhancement.

Abstract: This invention provides substituted acylanilide compounds and uses thereof in treating a variety of diseases or conditions in a subject including, inter alia, a muscle wasting disease and/or disorder such as Duchenne muscular dystrophy or Becker muscular dystrophy.